Preclinical establishment of a divalent vaccine against SARS-CoV-2
Z. Hevesi, D. Gerges, S. Kapps, R. Freire, S. Schmidt, D. Pollak, K. Schmetterer, T. Frey, R. Lang, W. Winnicki, A. Schmidt, T. Harkany, L. Wagner
This paper develops a divalent vaccine against SARS-CoV-2 that induces strong IgG responses and T-cell activation, showing durability and cross-variant protection.
bioRxiv · Feb 10, 2022Bioengineering